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Objective. The aim of this study is to analyze the efﬁcacy of colposcopic-guided laser-skinning colpectomy to
treat extended high-grade vaginal intraepithelial neoplasia (VaIN).
Methods. Retrospective review of 33 heavily pretreated patients with high-grade VaIN extending over
20–100% of the vaginal surface treated between 2003 and 2013 with colposcopic-guided laser-skinning
colpectomy. The vaginal epithelium including all VaIN lesions was excised in one piece with a depth of 2–3 mm.
Results. Vaginal cancer was diagnosed in 10 patients (nine microinvasive squamous cell carcinoma and one
vaginal carcinoma). No serious adverse events related to laser-skinning colpectomy were observed. Of 33
patients, 23 were followed up with cytology and colposcopy for at least 12 months at our institution (median
follow 26.5 months; range 12–104 months), while ﬁve had a shorter follow-up, four an external follow-up
and one patient was lost. Of 23 patients with follow-up ≥12 months, 20 were disease free after a single laser-
skinning colpectomy (overall cure rate 87.0%). Moderate shortening of the vagina was observed in two patients
and another two required reconstruction of vaginal strictures during long-term follow-up.
Conclusion. Laser-skinning colpectomy appears to be a feasible treatment for extended high-risk VaIN3. The
procedure avoids the mutilation associated with colpectomy and allows early diagnosis and staging of invasive
disease.© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Vaginal intraepithelial neoplasia (VaIN) is a rare premalignant lesion
deﬁned by squamous cell atypia without invasion [1–7], which affects
women from their late teens onwards [8]. The mean age at diagnosis
is approximately 50 years. The incidence of VaIN, estimated to be 0.2
to 0.3 cases per 100,000 women in the United States, appears to be
increasing, most likely as a result of increased awareness, expanded
cytological screening, and more widespread use of colposcopy [8,9]. Of
note, because of an increased prevalence of human papilloma virusy, Obstetrics and Gynecologic
7, 38440 Wolfsburg, Germany.
y).
. This is an open access article under(HPV) infection, younger women are more likely to be diagnosed with
VaIN than was the case 20 years ago [9].
An individualized treatment approach is required to balance the
persistent risk of disease recurrence with the need tominimizemorbid-
ity and preserve vaginal function [9]. Although the overall risk of inva-
sive progression is only approximately 3% [10], physicians need to be
mindful of underestimating larger lesions with malignant potential.
Additional factors to consider when selecting the appropriate treatment
for women with VaIN include prior hysterectomy, prior radiation
therapy, age, sexual activity, comorbidities and vaginal anatomy [11].
There is a broad consensus that patients with low-grade disease
(VaIN1) should be managed conservatively without any ablative or
destructive treatment, or with topical intravaginal application of estro-
gen [12–14]. A similarly conservative approach is appropriate for the
majority of patients with VaIN2 and selected cases with VaIN3 lesions.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. (A) Colposcopy before surgery in a woman aged 48 years. Aceto-white dysplastic
areas. (B) Atypical epithilium after use of Lugol solution in same patient. (C) Intraoperative
colposcopic view.
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and commonly used standard treatment for women with high-grade
lesions (VaIN2/3) [15]. The advantages of laser vaporization include
versatility in the treatment of multifocal disease without sacriﬁcing
the vaginal epithelium and a low likelihood of complications. Disadvan-
tages with this treatment approach include the inability to treat buried
vaginal cuff epithelium because of technical difﬁculties in applying the
laser to a folding and often distorted (cuff) surface within a conﬁned
space [16] and the possibility of overlooking invasive disease. The effec-
tiveness of laser vaporization for the treatment of VaIN has been report-
ed to range from 50 to 100% [17], althoughmost published studies were
retrospective, small, with short-term follow-up, and did not provide
detailed information about lesion size. Although laser vaporization is
generally safe and achieves good cure rates in patients with small
VaIN, usually covering an area of less than 1 cm2, the rate of recurrent
disease and the risk of overlooking occult invasive cancer are high in
patients with VaIN3 extending over more than 20% of the vaginal
surface, particularly if the vaginal cuff is involved [17].
Radical treatments for high-grade VaIN include irradiation or
colpectomy, but bothmethods are associatedwith the risk of potentially
life-changing complications such as severe vaginal shortening, ﬁbrosis,
and stenosis [18,19]. Such potentially mutilating procedures should be
avoided whenever possible in sexually active women, but are consid-
ered state-of-the-art treatment for patients with extended and/or
recurrent VaIN3, and for those with microinvasive cancer of the vagina.
In contrast to standard surgical procedures (Metzenbaum scissors
and scalpel), a high-magniﬁcation CO2 laser can cut tissue with little
bleeding and achieves an optimal, uniform cutting depthwith preserva-
tion of the excised specimen [20,21]. We therefore hypothesized that
selected patients with high-risk VaIN would beneﬁt from a novel
treatment procedure involving colposcopic-guided laser-skinning
colpectomy. The aim of this retrospective study was to evaluate our ex-
perience with laser-skinning colpectomy as an alternative to total or
partial colpectomy, or laser vaporization in the treatment of patients
with high-risk VaIN2/3.
Materials and methods
Patients
We conducted a retrospective review of medical records from the
Department of Gynecology at KlinikumWolfsburg, Germany to evaluate
patients with high-risk VaIN2/3 treatedwith laser-skinning colpectomy
between 2003 and 2013. High-risk VaIN lesions were deﬁned as those
covering a large area (at least 10 cm2) withmajor ﬁndings on colposco-
py, particularly ﬁndings conspicuous of microinvasion. We excluded
patients with low-grade disease and those with frank invasive cancer
of the vagina. Records from 118 patients with VaIN2/3 treated at our
institution were reviewed and cases where less than 20% of the vaginal
surface was involved were excluded. The study was approved by the
Ethics Committee Lower Saxony in Hanover, Germany.
In all cases, the diagnosis of VaIN was based on colposcopically
directed punch biopsies taken prior to laser-skinning colpectomy.
Colposcopy was performed using a Leisegang 1D LED colposcope at a
focal distance of 300 mm. The cervix, vagina, vulva, and perineal area
were inspected after application of 3% acetic acid. Punch biopsies were
taken to conﬁrm that all suspect lesions were at least extended VaIN2.
The presence of microinvasive disease was assessed using the
colpectomy specimen, rather than punch biopsies, because we consid-
ered this approach superior for precise histopathologic staging. If pres-
ent, all microinvasive cancers (deﬁned as lesions with an invasion
depth of 1–3 mm) were excised with clear margins. Colposcopy and
palpation were done to exclude the presence of frank invasive cancer
Possible prognostic factors evaluated included the grade, location,
and focality of the lesions, the age, follow-up period, and menopausal
status of the patients, the power and duration of laser ablation, thepresence of concurrent cervical or vulvar neoplasia, and previous
hysterectomy.Colposcopic-guided laser skinning colpectomy
Before treatment, the entire area of abnormal epithelium was
colposcopically inspected after applying 3% acetic acid followed by
Lugol (iodine) solution (Fig. 1). Application of Lugol solution is obligato-
ry for the assessment of vaginal neoplasia to determine the extent of
lesions and to avoid overlooking satellite lesions.
Fig. 3. (A and B) Histology: High-grade vaginal dysplasia with thermonecrosis.
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extensive laser experience while the patients were under general anes-
thesia. A CO2 laser (Limmer, Berlin, Germany)with a focused spot size of
less than 1mmand ameanpower of 8–12Wsuperpulsewas used. In all
cases, colpectomy was performed under colposcopic control and the
laser was guided using a micromanipulator with joystick connected
to the colposcope. The vaginawas circularly incised caudal to the lesion
zone and the tissue was then excised in one piece. We excised 20–100%
of the vaginal epithelium including all VaIN lesions in one piece with a
depth of 2–3 mm following the lamina vasorum (see Fig. 2). Saline
solution was applied repeatedly to minimize thermonecrosis of the
preserved basal layers of the vagina (Fig. 3). In women with a history
of hysterectomy the excision included the vaginal epithelium spreading
into the corners of vaultwith the adjacent part of the scar. Under colpos-
copy magniﬁcation the cutting line followed the individual anatomy
of the hysterectomy scars and resulted in a greater depth of excision
(5− 10mm). After excision, a tamponade with estriol was invaginated
to prevent adhesions of the vaginal walls.
Careful handling of the excised thin tissue is required because of sus-
ceptibility to damage. An excision of the complete squamous epithelium
of the vagina yields a 5 cm long specimen, showing dramatic shrinkage
compared with a length of 9–10 cm prior to excision. However, due to
the fragility of the excised tissue, tears and small incisions will occur
in most specimens (Fig. 4). Post-procedure colposcopy showed no
residual neoplastic tissue in the treated vagina (Fig. 5).
After treatment, patientswere instructed to apply a topical anesthet-
ic ointment (lidocaine 2%) to the treated vaginal area several times a day
for the ﬁrst 3–4 days and then as needed, and to use a local estrogen
cream until the ﬁrst follow-up appointment. In addition, patients were
advised to use a vaginal dilatator for at least half an hour twice daily
for 4 weeks, and then daily for 4 months to prevent adhesions of the
vaginal walls.
All patients were scheduled to have follow-up colposcopy. The ﬁrst
follow-up visit was 1 month after treatment in all cases. Subsequent
colposcopy and vulvar evaluation were performed every 3 months in
the ﬁrst year after treatment, every 6 months in the second year, and
annually thereafter. Pap smears were taken at months 3, 6, 12, and 24,
combined in some cases with HPV testing (Hybrid Capture 2/HC2;
Qiagen, Germany or Cobas/Roche Diagnostics, CA, USA) at months 6
and 24. Vaginal functionality was evaluated by clinical examination a
few days after the operation and by patient questioning at 12 months
using the Female Sexual Function Index (FSFI).Fig. 2. Excision following the lamina vasorum.The study objectives were to evaluate procedure-related morbidity,
freedom from disease, and vaginal function.
Results
Overall 33 of 118 patients with VaIN2/3 treated in our department
had lesions spreading over more than 20% of the vaginal surface and
were selected for laser-skinning colpectomy. VaIN was classiﬁed as
grade 3 in 19 patients and grade 2 in four patients, while 10 cases of vag-
inal carcinoma were diagnosed, including nine cases of microinvasive
squamous cell carcinoma with depth of invasion of 3 mm or less.
The mean age of patients included in this analysis was 61.5 years
(range 46 to 82 years) and 27 patients (82%) were postmenopausal at
the time of operation. Other patient characteristics are shown in the
Table 1. All patients except one had undergone at least one previous
gynecological operation (Table 2).
The extent of laser-skinning colpectomy procedures was ‘partial’
(20–65% of the surface) in 22 patients (67%), ‘subtotal’ (66–90% of
surface) in eight patients (24%), and ‘total’ (N90%) in three patients
(9%). The duration of the procedure was approximately 1 min per
percentage of vagina excised, corresponding to a time of 100 min for
total colpectomy.
In all cases, laser-skinning colpectomy was performed without
signiﬁcant complications and no serious adverse events were observed.
Blood loss of 250 ml was reported in one patient, but was less than
100ml in all other cases. Noperioperative complicationswere observed.
The median duration of hospital stay was 8 days (range 2–16 days).
Fig. 4. (A) Macroscopical colpectomy preparation. Vaginal tissue with a swab in the vaginal
lumen (cranial view). Perforations are due to manipulations of the fragile specimen during
the operation. (B) The excised tissues shrink signiﬁcantly (60–80%) during laser excision.
Table 1
Characteristics of women with VaIN.
n %
Smoking at diagnosis
Non-smoker 22 66.7
Smoker 7 21.1
Unknown 4 12.1
Previous hysterectomy
No 4 12.0
Not for neoplasia 14 42.5
For neoplasia 15 45.5
Previous CIN/VIN
No 16 48.5
Yes 17 51.5
Previous irradiation
No 28 84.8
Yes 5 15.2
Proportion of the vagina affected a
b50% 15 46.9
50–100% 17 53.1
CIN = cervical intraepithelial neoplasia; VIN = vulvar intraepithelial neoplasia.
a Data missing from one patient.
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least 12 months with cytological examination and colposcopy to assess
therapeutic response.Median follow-up of this cohort was 26.5 monthsFig. 5. Colposcopy 3 weeks after laser-skinning colpectomy showing normal re-epitheliated
tissue and no signs of dysplasia.(range: 12–104 months). Five patients had a follow-up of less than
12 months at our institution, while another ﬁve patients were treat-
ed in 2013 and, therefore, had not yet entered long-term follow-up
at the time of this analysis; the follow-up duration in this cohort
was 3–9 months.
Of the 23 patients with sufﬁcient follow-up, 20 were disease free
following a single laser-skinning colpectomy, corresponding to an over-
all cure rate of 87.0%. Two patients withmicroinvasive cancers had local
recurrence, one with recurrent carcinoma and the other with recurrent
VaIN. Laparoscopic follow-up lymphadenectomy and further staging
procedures were performed in three patients with a depth of invasion
of 3 mm (n = 2) or more (n = 1). The latter patient was found to
have previously undiagnosed distant metastases at the time of laser-
skinning colpectomy. The patient had vaginal shortening from previous
treatment and previously undetected tumor was identiﬁed in scar
tissue. Lymphadenectomy revealed positive lymph nodes and she was
classiﬁed as having stage IV disease requiring systemic therapy.
Therewere no recurrences reported among15 patientswith extend-
ed VaIN3 without invasive cancer during 12–104 months of follow-up.
Laser-skinning colpectomy was successful in 8 of 10 patients with a
follow-up duration shorter than 12 months, while two had a small area
recurrence 4 months after the ﬁrst surgery was performed. Both cases
were successfully treated with laser vaporization.
HPV test results were available for 16 of 23 patients with sufﬁcient
follow-up and all tested positive for high-risk HPV-DNA before the
procedure. Following laser-skinning colpectomy, 11 of 16 (68.8%) tested
HPV-negative 6 to 24 months after the operation. All cases with HPV
clearance remained disease free during the entire follow-up period,
while one of ﬁve cases with HPV persistency developed a new VaIN3
lesion in an untreated part of the vagina.
Vaginal functionality was evaluated in all patients a few days after
laser-skinning colpectomy and ﬁndings were normal in all cases.Table 2
Prior operations in 33 women with VaIN (some patients received multiple treatments).
Type of surgery n %
Hysterectomy 26 78.8
Radical hysterectomy 3 9.1
Conization 7 21.2
Partial colpectomy 3 9.1
Laser vaporization 5 15.2
Vulva excision 3 9.1
No operation 1 3.0
Illustration with depth of laser excision (Fig. 2) was created by Kathrin
Plaschke.
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long-term follow-up assessments beyond 12 months were performed
at our institution. However, long-term data were not available for ﬁve
patients treated 1–9 months before this analysis, another four had
normal follow-up assessments with their local gynecologist, and one
was lost to follow-up. Among 23 patients followed up for longer than
12 months at our institution, the majority (56.5%) retained 100%
functionality of the vagina, whereas 17.4% had a partial stenosis of the
vagina postoperatively. Of note, in most cases, partial stenosis occurred
as a 2–3 mm strong scar stricture of one of the side walls, with approx-
imately 20% occlusion of the vagina, and could be easily corrected by
outpatient laser surgery and subsequent dilatations. In the remaining
26.1% of cases, vaginal deformities were already present preoperatively.
Typically, patients with preoperative deformities showed improvement
in vaginal function after laser-skinning colpectomy because we also
excised scars and strictures. Among 14 patients with extended VaIN3,
10 patients had no loss in vaginal function, while two showed mod-
erate shortening of the vagina, and two required reconstruction of
vaginal strictures. Furthermore, all women who were sexually active
before the operation maintained 100% functionality of the vagina
postoperatively.
Discussion
In this retrospective study, we demonstrated that colposcopic-
guided laser-skinning colpectomy is a feasible treatment option for
selected patients with extended high-risk VaIN2/3 and microinvasive
cancer.
Patients selected for this novel excisional procedure were classiﬁed
as high-risk VaIN2/3 and may be considered as potential candidates
for conventional radical treatment with laser vaporization, radiothera-
py, or partial or total colpectomy [22]. Each of thesemethods has advan-
tages and disadvantages and many authors have reported good results,
particularly using laser vaporization [17,21,23]. CO2 laser vaporization is
successful in up to 95% of cases and is associated with a low rate of peri-
and postoperativemorbidity [24]. However, although laser vaporization
preceded by a careful colposcopic evaluation with punch biopsies is an
efﬁcient therapeutic approach for most VaIN lesions, this treatment
modality may be potentially harmful in patients with extended lesions
when invasive disease is overlooked. While vaporization of VaIN with
early stromal invasion of less than 1 mm is considered futile, deeper
inﬁltrating cancersmay escape destruction and ﬁnally result in a poten-
tially lethal disease, such as we observed in one patient with cancer
detected in vaginal scars following multiple treatments with laser
vaporization. Our highly selected cohort of heavily pretreated patients
presented with lesions that on average covered more than half of the
vagina and had a high risk of underlying invasive disease. In addition
to prior surgical procedures, the majority of patients had received
topical estrogen therapy.
In this rare subgroup of women with extended VaIN3 lesions, laser-
skinning colpectomy achieved an overall cure rate greater than 80%
with a low morbidity, comparable to extended laser vaporization. In
experienced hands, laser-skinning colpectomy is an efﬁcient procedure
that can be completed in approximately 100min for a total colpectomy.
Except for some manageable blood loss, we did not observe any
signiﬁcant peri-operative morbidity. Long-term follow-up showed
that vaginal function is generally well preserved following laser-
skinning colpectomy, which offers an important advantage over sur-
gical colpectomy, particularly for sexually active women. Vaginal func-
tionality was completely preserved in all sexually active women,
suggesting that regular intercourse may prevent the formation of
stenoses.
Partial colpectomy, or upper vaginectomy, is widely accepted as a
treatment option for patients with VaIN, including those with high-
risk disease [19,25]. Upper vaginectomy appears to be a relatively safe
procedure, with a low rate of postoperative complications, and providesa specimen for histologic review [19]. Laser-skinning colpectomy offers
a less invasive alternative to conventional colpectomy and the use of a
colposcopically guided CO2 laser gives more precise control of cutting
depth, which is a particularly important consideration in challenging
anatomic locations such as the vaginal vault and for the treatment of
extensive high-risk VaIN lesions. In contrast to destructive methods,
laser-skinning colpectomy allows a complete histologic examination
with exact staging of underlying early invasive disease, which is not
possible with punch biopsies. The area of thermonecrosis was less
than 0.2mmwith this procedure and did not interferewith pathological
assessment (see Fig. 3).
VaIN is a rare premalignant lesion and this analysis is therefore
limited by the small number of patients included, particularly as the
focus of our analysis is the subset of women with extended VaIN2/3
lesions. Furthermore, at present we cannot deﬁne the best selection
criteria for ‘extension of the lesion’. We used a cut-off of 20% in this
study, but do not know if a different cut-off (30 or 50%) would improve
patient selection. Nevertheless, the cohort evaluated in this study is
representative of heavily pretreated patients with high-risk VaIN
referred for treatment at specialist centers. In addition, the duration of
follow-up was less than 12 months in 10 of 33 patients. The true loss
to follow-up was lower because some patients referred to Wolfsburg
from distant locations preferred to be followed up at their local centers.
Long-term follow-up is imperative because of the propensity of this
disease to recur following treatment [12]. The risk for recurrence
appears to be linked with persistent HPV infection [26]. In the present
study, 68.8% of women with a positive HPV status at baseline tested
negative following laser-skinning colpectomy. Patients with persistent
HPV infection usually relapse rapidly, within 12 months, whereas we
observed a low risk for recurrence (approximately 20%).
This analysis did not include control groups and we cannot make
deﬁnitive conclusions about the efﬁcacy and safety of laser-skinning
colpectomy compared with conventional radical interventions or a
more conservative approach. Furthermore, although laser-skinning
colpectomy may be a treatment option for patients with microinvasive
cancer up to a depth of invasion of less than 3 mm with free margins,
our dataset is not sufﬁciently robust to allow deﬁnitive conclusions to
be made for this subgroup.
Management of patients with VaIN requires an individualized
treatment plan [13] and a conservative approach is appropriate for
VaIN1 and most VaIN2 lesions, while laser vaporization is usually
the most effective treatment for small VaIN2/3 lesions. However,
we have no data to suggest that laser-skinning colpectomy can en-
tirely replace conventional, radical colpectomy or if cases with
deep involvement of the hysterectomy scar may ﬁnally beneﬁt
from a more radical approach. Colposcopic-guided laser-skinning
colpectomy should therefore be considered only for appropriately
selected patients with biopsy-proven VaIN3 or VaIN2 covering
more than 20% of the vaginal surface.Disclosure of ﬁnancial support/funding
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